For the last 20 years MIT Technology Review’s Breakthrough Technologies 2020 has been assessing the way we live, work and invest.
With an availability horizon of 3-5 years, AI-discovered molecules are hot, Insilico Medicine‘s research together with the University of Toronto was highlighted.
‘The ability of deep learning and other AI tools to find novel molecules with desirable properties will transform drug discovery. It promises to make the development of new medicines far faster and more effective, and is an important new tool in the hunt for better drugs. Insilico Medicine has been a leader in using some of the most exciting techniques in AI, such as GANs [Generative Adversarial Networks], for drug discovery. And, with the latest results, GANs is proving to be a powerful new tool for finding promising molecules.’ said David Rotman, Editor at Large.
Insilco have been at this for some time and have been hitting their stride. The five-year-old artificial intelligence software developer last week published, on its website, the molecular structure of several hundred chemical compounds, which are designed to work on a key “target” of the coronavirus. It is now seeking feedback from medicinal chemists, and aims to synthesise and test up to 100 of them with partners .
On the same day, Insilico Medicine announced the launch of its Entrepreneur in Residence program in brain cancers with the objective to externalize the effort before August, 2020. The program will be led by pharma industry expert and seasoned R&D scientist, Dr. George Okafo.
“I remember the first AI and drug discovery conferences in early 2016 when we presented the first theoretical basis for using the Adversarial Autoencoders (AAE) for the generation of new molecular structures with desired properties. I had to spend a lot of time explaining the principles using images and the deep learning folks did not get the chemistry part and chemists were lost in math and asked for experimental validation. No one took it seriously. Now, most pharmaceutical companies started their internal generative chemistry groups. I am very happy to see that,” said Alex Zhavoronkov, PhD, co-founder, and CEO of Insilico Medicine.